Living with idiopathic pulmonary fibrosis (IPF)?

Find out if the ISABELA study may be an option for you.

What is idiopathic pulmonary fibrosis (IPF)?

IPF is a chronic lung disease that makes it hard to breathe normally. Doctors expect more people to be diagnosed with IPF at a higher rate in the coming years, and there is no cure for the disease. In the ISABELA study, doctors hope they can find out if the investigational drug can slow down how quickly IPF progresses. People who take part will receive study medication or placebo in addition to the normal prescribed treatment.


The ISABELA studies are enrolling now

The ISABELA clinical studies are researching an investigational add-on medication, GLPG1690, for people with idiopathic pulmonary fibrosis (IPF). In this context, an “add-on” medicine is something you take in addition to your standard treatment from your doctor. There are two identical designed studies being conducted in order to verify the results.

The main purpose of these studies is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated. If you are interested in participating, visit the Frequently Asked Questions or look for a study center in your area.

Study Center Locator

Study participants will receive:

  • Study medication
  • Study-related medical care
  • Reimbursement for expenses

You may qualify to participate if you are:

  • 40 years of age or older
  • Diagnosed with idiopathic pulmonary fibrosis (IPF) for less than 5 years

Q&A about the study: